Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs

• Autors principals: Sandra M. Axiak‐Bechtel (Autor), Stacey B. Leach (Autor), David G. Scholten (Autor), Jessica R. Newton‐Northup (Autor), Brendan J. Johnson (Autor), H. E. Durham (Autor), Kenneth A. Gruber (Autor), Michael F. Callahan (Autor)
• Format: Llibre
• Publicat: Wiley, 2021-05-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high‐ (2.25 mg kg−1) (n = 5) a...